Literature DB >> 12153400

The type 2 vascular endothelial growth factor receptor recruits insulin receptor substrate-1 in its signalling pathway.

Duraisamy Senthil1, Goutam Ghosh Choudhury, Basant K Bhandari, Balakuntalam S Kasinath.   

Abstract

Vascular endothelial growth factor (VEGF) isoforms exert their biological effects through receptors that possess intrinsic tyrosine kinase activity. Whether VEGF binding to its receptors recruits insulin receptor substrate (IRS) family of docking proteins to the receptor is not known. Following incubation of mouse kidney proximal tubular epithelial cells with VEGF, we observed an increase in tyrosine phosphorylation of several proteins, including one of approximately 200 kDa, suggesting possible regulation of phosphorylation of IRS proteins. VEGF augmented tyrosine phosphorylation of IRS-1 in kidney epithelial cells and rat heart endothelial cells in a time-dependent manner. In the epithelial cells, association of IRS-1 with type 2 VEGF receptor was promoted by VEGF. VEGF also increased association of IRS-1 with the p85 regulatory subunit of phosphoinositide 3-kinase (PI 3-kinase), and PI 3-kinase activity in IRS-1 immunoprecipitates was increased in VEGF-treated cells. Incubation of epithelial cells with antisense IRS-1 oligonucleotide, but not sense oligonucleotide, reduced expression of the protein and VEGF-induced PI 3-kinase activity in IRS-1 immunoprecipitates. Additionally, VEGF-induced protein synthesis was also impaired by antisense but not sense IRS-1 oligonucleotide. These data provide the first evidence that binding of VEGF to its type 2 receptor promotes association of IRS-1 with the receptor complex. This association may account for some of the increase in VEGF-induced PI 3-kinase activity, and the increase in de novo protein synthesis seen in renal epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12153400      PMCID: PMC1222964          DOI: 10.1042/BJ20020137

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

Review 1.  FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition.

Authors:  M J Cross; L Claesson-Welsh
Journal:  Trends Pharmacol Sci       Date:  2001-04       Impact factor: 14.819

2.  Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation.

Authors:  V Dayanir; R D Meyer; K Lashkari; N Rahimi
Journal:  J Biol Chem       Date:  2001-03-08       Impact factor: 5.157

3.  Insulin regulation of protein translation repressor 4E-BP1, an eIF4E-binding protein, in renal epithelial cells.

Authors:  B K Bhandari; D Feliers; S Duraisamy; J L Stewart; A C Gingras; H E Abboud; G G Choudhury; N Sonenberg; B S Kasinath
Journal:  Kidney Int       Date:  2001-03       Impact factor: 10.612

4.  Activation of renal signaling pathways in db/db mice with type 2 diabetes.

Authors:  D Feliers; S Duraisamy; J L Faulkner; J Duch; A V Lee; H E Abboud; G G Choudhury; B S Kasinath
Journal:  Kidney Int       Date:  2001-08       Impact factor: 10.612

Review 5.  Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family.

Authors:  I Zachary; G Gliki
Journal:  Cardiovasc Res       Date:  2001-02-16       Impact factor: 10.787

6.  Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration.

Authors:  S Dimmeler; E Dernbach; A M Zeiher
Journal:  FEBS Lett       Date:  2000-07-21       Impact factor: 4.124

7.  Angiotensin II inhibits insulin-stimulated phosphorylation of eukaryotic initiation factor 4E-binding protein-1 in proximal tubular epithelial cells.

Authors:  D Senthil; J L Faulkner; G G Choudhury; H E Abboud; B S Kasinath
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

8.  Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation.

Authors:  L W Wu; L D Mayo; J D Dunbar; K M Kessler; M R Baerwald; E A Jaffe; D Wang; R S Warren; D B Donner
Journal:  J Biol Chem       Date:  2000-02-18       Impact factor: 5.157

9.  Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells.

Authors:  S Kanno; N Oda; M Abe; Y Terai; M Ito; K Shitara; K Tabayashi; M Shibuya; Y Sato
Journal:  Oncogene       Date:  2000-04-20       Impact factor: 9.867

10.  Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.

Authors:  D Fulton; J P Gratton; T J McCabe; J Fontana; Y Fujio; K Walsh; T F Franke; A Papapetropoulos; W C Sessa
Journal:  Nature       Date:  1999-06-10       Impact factor: 49.962

View more
  10 in total

1.  Grb-2-associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A-endothelial NOS pathway.

Authors:  Yao Lu; Yan Xiong; Yingqing Huo; Jingyan Han; Xiao Yang; Rongli Zhang; De-Sheng Zhu; Stefan Klein-Hessling; Jun Li; Xiaoyu Zhang; Xiaofan Han; Yanli Li; Bin Shen; Yulong He; Masabumi Shibuya; Gen-Sheng Feng; Jincai Luo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

Review 2.  Regulation of mRNA translation in renal physiology and disease.

Authors:  Balakuntalam S Kasinath; Denis Feliers; Kavithalakshmi Sataranatarajan; Goutam Ghosh Choudhury; Myung Ja Lee; Meenalakshmi M Mariappan
Journal:  Am J Physiol Renal Physiol       Date:  2009-06-17

3.  Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis.

Authors:  Zhefu Ma; Shannon L Gibson; Maura A Byrne; Junran Zhang; Morris F White; Leslie M Shaw
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

4.  Tyrosine phosphorylation of insulin receptor substrates during ischemia/reperfusion-induced apoptosis in rat liver.

Authors:  Raffaele Cursio; Claudia Miele; Nathalie Filippa; Pascal Colosetti; Patrick Auberger; Emmanuel Van Obberghen; Jean Gugenheim
Journal:  Langenbecks Arch Surg       Date:  2008-08-05       Impact factor: 3.445

5.  Glycogen synthase kinase 3beta is a novel regulator of high glucose- and high insulin-induced extracellular matrix protein synthesis in renal proximal tubular epithelial cells.

Authors:  Meenalakshmi M Mariappan; Megan Shetty; Kavithalakshmi Sataranatarajan; Goutam Ghosh Choudhury; Balakuntalam S Kasinath
Journal:  J Biol Chem       Date:  2008-08-12       Impact factor: 5.157

6.  Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1.

Authors:  Tram Anh Tran; Lisa Kinch; Samuel Peña-Llopis; Lutz Kockel; Nick Grishin; Huaqi Jiang; James Brugarolas
Journal:  Mol Cell Biol       Date:  2013-07-22       Impact factor: 4.272

7.  The phosphotyrosine interactome of the insulin receptor family and its substrates IRS-1 and IRS-2.

Authors:  Stefan Hanke; Matthias Mann
Journal:  Mol Cell Proteomics       Date:  2008-11-11       Impact factor: 5.911

8.  Endothelial Insulin Receptors Promote VEGF-A Signaling via ERK1/2 and Sprouting Angiogenesis.

Authors:  Andrew M N Walker; Nele Warmke; Ben Mercer; Nicole T Watt; Romana Mughal; Jessica Smith; Stacey Galloway; Natalie J Haywood; Taha Soomro; Kathryn J Griffin; Stephen B Wheatcroft; Nadira Y Yuldasheva; David J Beech; Peter Carmeliet; Mark T Kearney; Richard M Cubbon
Journal:  Endocrinology       Date:  2021-08-01       Impact factor: 4.736

9.  Expression and function of the insulin receptor substrate proteins in cancer.

Authors:  Katerina Mardilovich; Shannon L Pankratz; Leslie M Shaw
Journal:  Cell Commun Signal       Date:  2009-06-17       Impact factor: 5.712

10.  Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a 'first in man' phase I investigation.

Authors:  Hermann Kain; David Goldblum; Bernard Geudelin; Eric Thorin; Christoph Beglinger
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.